152 related articles for article (PubMed ID: 37907716)
1. Decreased eukaryotic initiation factors expression upon temozolomide treatment-potential novel implications for eIFs in glioma therapy.
Krassnig S; Leber SL; Orthmann A; Golob-Schwarzl N; Huber HJ; Wohlrab C; Skofler C; Pennauer M; Raicht A; Birkl-Toeglhofer AM; Naumann M; Mahdy-Ali K; von Campe G; Leoni M; Alcaniz J; Hoffmann J; Wälchli T; Weis S; Benesch M; Haybaeck J
J Neurooncol; 2023 Oct; 165(1):91-100. PubMed ID: 37907716
[TBL] [Abstract][Full Text] [Related]
2. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
3. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
4. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway.
Liu X; Wang L; Chen J; Ling Q; Wang H; Li S; Li L; Yang S; Xia M; Jing L
Mol Med Rep; 2015 Feb; 11(2):1516-22. PubMed ID: 25351348
[TBL] [Abstract][Full Text] [Related]
6. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
7. FOXM1-mediated NUF2 expression confers temozolomide resistance to human glioma cells by regulating autophagy via the PI3K/AKT/mTOR signaling pathway.
Guo L; Wu Z
Neuropathology; 2022 Oct; 42(5):430-446. PubMed ID: 35701983
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy.
Tomar VS; Patil V; Somasundaram K
Cell Biol Toxicol; 2020 Jun; 36(3):273-278. PubMed ID: 31758290
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
10. Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation.
Grogan PT; Sarkaria JN; Timmermann BN; Cohen MS
Invest New Drugs; 2014 Aug; 32(4):604-17. PubMed ID: 24718901
[TBL] [Abstract][Full Text] [Related]
11. LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway.
Chen L; Han L; Shi Z; Zhang K; Liu Y; Zheng Y; Jiang T; Pu P; Jiang C; Kang C
Mol Med Rep; 2012 Feb; 5(2):575-9. PubMed ID: 22086271
[TBL] [Abstract][Full Text] [Related]
12. MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway.
Kong S; Cao Y; Li X; Li Z; Xin Y; Meng Y
J Cell Mol Med; 2020 Apr; 24(8):4677-4686. PubMed ID: 32181582
[TBL] [Abstract][Full Text] [Related]
13. MiR-223/PAX6 Axis Regulates Glioblastoma Stem Cell Proliferation and the Chemo Resistance to TMZ via Regulating PI3K/Akt Pathway.
Huang BS; Luo QZ; Han Y; Huang D; Tang QP; Wu LX
J Cell Biochem; 2017 Oct; 118(10):3452-3461. PubMed ID: 28332226
[TBL] [Abstract][Full Text] [Related]
14. The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
Chen PH; Cheng CH; Shih CM; Ho KH; Lin CW; Lee CC; Liu AJ; Chang CK; Chen KC
PLoS One; 2016; 11(11):e0167096. PubMed ID: 27893811
[TBL] [Abstract][Full Text] [Related]
15. Daurisoline suppress glioma progression by inhibiting autophagy through PI3K/AKT/mTOR pathway and increases TMZ sensitivity.
Yin HT; Hui-Lu ; Yang JH; Li Q; Li M; Zhao QQ; Wen ZP
Biochem Pharmacol; 2024 May; 223():116113. PubMed ID: 38460907
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of circHIPK3 Facilitates Temozolomide Sensitivity in Glioma by Regulating Cellular Behaviors Through miR-524-5p/KIF2A-Mediated PI3K/AKT Pathway.
Yin H; Cui X
Cancer Biother Radiopharm; 2021 Sep; 36(7):556-567. PubMed ID: 32833501
[No Abstract] [Full Text] [Related]
17. Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo.
Bai Y; Chen Y; Hong X; Liu X; Su X; Li S; Dong X; Zhao G; Li Y
Sci Rep; 2018 Jul; 8(1):11470. PubMed ID: 30065314
[TBL] [Abstract][Full Text] [Related]
18. Amrubicin encapsulated PLGA NPs inhibits the PI3K/AKT signaling pathway by activating PTEN and inducing apoptosis in TMZ-resistant Glioma.
Younis M; Shaikh S; Shahzad KA; Tan F; Wang Z; Lashari MH
Biomed Mater; 2024 Jan; 19(2):. PubMed ID: 38181444
[TBL] [Abstract][Full Text] [Related]
19. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
Li C; Feng S; Chen L
Mol Cell Biochem; 2021 Feb; 476(2):699-713. PubMed ID: 33106913
[TBL] [Abstract][Full Text] [Related]
20. lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K/AKT pathway in glioma.
Zhou J; Xu N; Liu B; Wang C; He Z; Lenahan C; Tang W; Zeng H; Guo H
Cancer Sci; 2022 Aug; 113(8):2681-2692. PubMed ID: 35637600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]